What is ACT Genomics Taiwan?
ACT Genomics Taiwan is a prominent cancer solution provider specializing in precision medicine services across Taiwan, Singapore, Hong Kong, and Japan. The company leverages a multidisciplinary team of experts in tumor biology, cancer genomics, and bioinformatics to deliver comprehensive treatment guidelines. Their services encompass management of solid tumors, relapse, drug resistance, as well as cancer monitoring, risk assessment, and immunotherapy evaluation, aiming to enhance patient outcomes through advanced molecular diagnostics.
How much funding has ACT Genomics Taiwan raised?
ACT Genomics Taiwan has raised a total of $20.5M across 2 funding rounds:
Series A
$8M
Series B
$12.5M
Series A (2015): $8M, investors not publicly disclosed
Series B (2016): $12.5M led by President International Development and UMC Capital
Key Investors in ACT Genomics Taiwan
President International Development
President International Development Corporation (PIDC) is the investment holdings company of the Uni-President Group, responsible for leading major investment projects and expanding the Group's business scope across food manufacturing, retail, international trade, and investment/finance services.
UMC Capital
UMC Capital is a leading global semiconductor foundry company providing high-quality IC fabrication services, focusing on logic and specialty technologies to serve major sectors of the electronics industry.
What's next for ACT Genomics Taiwan?
With its recent enterprise-level funding, ACT Genomics Taiwan is poised for accelerated expansion and innovation. The company's focus on precision medicine and advanced genomic analysis suggests a strategic direction towards scaling its service offerings and potentially entering new markets. Continued investment will likely fuel research and development, enhancing their diagnostic capabilities and solidifying their position as a leader in cancer care solutions within the Asia-Pacific region.
See full ACT Genomics Taiwan company page
